Class Action Alert for Geron Corporation Shareholders
The Gross Law Firm recently announced important information for shareholders of Geron Corporation (NASDAQ: GERN).
Who Should Pay Attention?
Shareholders who purchased shares of GERN during the specified class period are encouraged to reach out to the law firm about a potential lead plaintiff appointment. Remember, being appointed as a lead plaintiff is not essential to join in any recovery.
Details of the Class Period and Allegations
CLASS PERIOD: From February 28, 2024, to February 25, 2025.
ALLEGATIONS: The allegations state that Geron Corporation's representatives communicated misleading information to investors about the performance and launch potential of Rytelo (imetelstat). Supposedly, these statements gave investors confidence in Geron’s planned handling of the significant unmet medical needs related to the drug. However, concerns surrounding the drug's weekly monitoring requirements, competition, and seasonal performance were downplayed.
On February 26, 2025, the company revealed financial results that indicated Rytelo's sales had not met expectations. Factors contributing to this decline included market competition, a lack of awareness among potential users, and the challenges posed by the monitoring requirement. Consequently, Geron’s stock suffered a dramatic plunge. The share price fell from $2.37 on February 25, 2025, to $1.61 by February 26, marking an astonishing drop of about 32.07% in a single trading session.
Important Deadlines for Shareholders
DEADLINE: May 12, 2025 — Shareholders are advised to act promptly to ensure their registration in the class action. This is a crucial step toward participation in the case.
Next Steps for Shareholders
By registering as a shareholder who obtained GERN shares during the relevant timeframe, participants will gain access to ongoing updates through a dedicated portfolio monitoring service. The May 12 deadline is also the date by which interested parties must seek lead plaintiff status. Participation involves no fees or obligations from the shareholders.
About The Gross Law Firm
The Gross Law Firm is a recognized name in the field of class action litigation. Their mission focuses on advocating for the rights of investors who have been misled or have suffered losses due to unethical business practices. This firm strives for accountability among corporations regarding the truthfulness of their statements and their corporate responsibilities.
As part of their commitment, they assist investors in recovering losses stemming from false statements or material omissions that led to inflated stock valuations. Potential investors are encouraged to stay informed.
Company Contact Information
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the main focus of the class action lawsuit?
The lawsuit primarily addresses shareholder losses related to misleading statements about Geron Corporation's drug, Rytelo.
Who can participate in this class action?
All shareholders who purchased GERN shares between February 28, 2024, and February 25, 2025, are eligible to participate.
What are the necessary steps for shareholders?
Shareholders need to register their information and they can do so by contacting the Gross Law Firm.
What is the deadline for registration?
The registration deadline to be included in this class action is May 12, 2025.
What happens once I register?
Registered shareholders will receive updates about the ongoing case and can opt to become a lead plaintiff if interested.
